Indications and uses
• temporarily relieves itching and redness caused by pollen, ragweed, grass, animal hair and dander.
• temporarily relieves itching and redness caused by pollen, ragweed, grass, animal hair and dander.
• Adults and children 6 years of age and older: Instill 1 or 2 drops in the affected eye(s) up to 4 times daily. • Children under 6 years: ask a doctor
Naphazoline HCl (0.02675%)
Pheniramine maleate (0.315%)
Redness reliever
Antihistamine
If swallowed, get medical help or contact a Poison Control Center right away. Accidental oral ingestion in infants and children may lead to coma and marked reduction in body temperature.
benzalkonium chloride, boric acid, edetate disodium, hypromellose, purified water, sodium borate, sodium chloride. Hydrochloric acid may be used to adjust pH.
Call: 1-866-767-9161
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 59779-042-32 | 2025-01-23 | C162847 | 48780-1 | 9d75b9d0-a6db-f424-e053-dadaa90a57ce | Drug Facts |
| 59779-042-32 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-a6db-f424-e053-dadaa90a57ce | Drug Facts |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| NAPHAZOLINE HYDROCHLORIDE | ACTIVE INGREDIENT | MZ1131787D | 3 | |
| PHENIRAMINE MALEATE | ACTIVE INGREDIENT | NYW905655B | 3 | |
| NAPHAZOLINE | ACTIVE MOIETY | H231GF11BV | 3 | |
| PHENIRAMINE | ACTIVE MOIETY | 134FM9ZZ6M | 3 | |
| BENZALKONIUM CHLORIDE | INACTIVE INGREDIENT | F5UM2KM3W7 | 3 | |
| BORIC ACID | INACTIVE INGREDIENT | R57ZHV85D4 | 3 | |
| EDETATE SODIUM | INACTIVE INGREDIENT | MP1J8420LU | 3 | |
| HYDROCHLORIC ACID | INACTIVE INGREDIENT | QTT17582CB | 3 | |
| HYPROMELLOSES | INACTIVE INGREDIENT | 3NXW29V3WO | 3 | |
| SODIUM BORATE | INACTIVE INGREDIENT | 91MBZ8H3QO | 3 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 3 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 59779-042 | 59779-042-32 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| NAPHAZOLINE HYDROCHLORIDE | MZ1131787D | ACTIB |
| PHENIRAMINE MALEATE | NYW905655B | ACTIB |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
| BORIC ACID | R57ZHV85D4 | IACT |
| EDETATE SODIUM | MP1J8420LU | IACT |
| HYPROMELLOSES | 3NXW29V3WO | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM BORATE | 91MBZ8H3QO | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / AURICULAR (OTIC) | 0.37 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAOCULAR | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / ENDOTRACHEAL | 68 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | TABLET, FILM COATED / ORAL | ADJ PH | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SUSPENSION / AURICULAR (OTIC) | 0.6 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / ENDOTRACHEAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 360 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SPRAY / NASAL | 10 ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACAUDAL | 210 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / PARENTERAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRASPINAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / OPHTHALMIC | 0.31 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRADERMAL | 7 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | AEROSOL, FOAM / TOPICAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 1.5 %w/w | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, ORALLY DISINTEGRATING / ORAL | 41 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / TOPICAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRATHECAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRA-ARTERIAL | 278 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | EMULSION / OPHTHALMIC | 0.11 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRATHECAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVASCULAR | 0.86 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | TABLET / ORAL | 2.32 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / PERIDURAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INFILTRATION | 3535 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SUSPENSION / INTRAVENOUS | ADJ PH | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRALESIONAL | 1 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | LOTION / TOPICAL | 0.1 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / NASAL | 330 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / SUBCUTANEOUS | ADJ PH | ||
| EDETATE SODIUM | EDETATE SODIUM | MP1J8420LU | TABLET / ORAL | 5 mg | ||
| EDETATE SODIUM | EDETATE SODIUM | MP1J8420LU | SOLUTION / OPHTHALMIC | 0.1 %w/v | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | JELLY / TOPICAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE / ORAL | 6 mg | ||
| EDETATE SODIUM | EDETATE SODIUM | MP1J8420LU | SPONGE / TOPICAL | 0.14 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GEL / OPHTHALMIC | 0.9 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRACAVITARY | ADJ PH | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 0.53 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / PARENTERAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION, EXTENDED RELEASE / ORAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / AURICULAR (OTIC) | 3 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION/ DROPS / TOPICAL | ADJ PH | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | SUSPENSION/ DROPS / OPHTHALMIC | 0.03 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / AURICULAR (OTIC) | 18 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIAL | 1.35 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAPERITONEAL | 0.54 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | POWDER, FOR SUSPENSION / ORAL | 125 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / IONTOPHORESIS | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, DENTIFRICE / DENTAL | 0.03 mg/mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | DROPS / OPHTHALMIC | 1 %w/w | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | SHAMPOO / TOPICAL | 3 %w/w | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRADERMAL | ADJ PH |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N020065-001 | OPCON-A | NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N020065-001 | OPCON-A | 0.02675%;0.315% | SOLUTION/DROPS / OPHTHALMIC | RLD, RS | 1994-06-08 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 2c62608d-9812-920a-e063-6394a90a1d32 | 35a6bb06-efa2-4482-938b-66b6d41ab823 | 2025-01-23 | Warnings | 35a6bb06-efa2-4482-938b-66b6d41ab823 |
Adverse event summaries are temporarily unavailable. Other product information remains available.